Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03420833 · ClinicalTrials.gov registry record · NA
Metabolic Mapping and Cardiac Resynchronization
A NA study, sponsored by Yong-Mei Cha.
- Completed
- Registry status
- NA
- Development phase
- 82
- Enrollment target
NCT03420833: Completed NA study, sponsored by Yong-Mei Cha.
NCT03420833 is a NA study that has completed, run by Yong-Mei Cha. The registered enrollment target is 82 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03420833, a NA study, has completed, sponsored by Yong-Mei Cha.
- COMPLETED
- Registry status
- NA
- Development phase
- 82 participants
- Enrollment target
Study Summary
The purpose of this study is to gather information on the safety and effectiveness of cardiac resynchronization therapy (CRT) in patients who have mild heart failure (HF) and left bundle branch block (LBBB).
Primary Outcome
LVESVI is the volume of blood in the left ventricle at the end of contraction, or systole, adjusted for the individual's body surface area.
Interventions
- DEVICE Cardiac resynchronization therapy pacemaker (CRT-P)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2018-08-20 |
| Est. Completion | 2023-12-19 |
| Phase | NA |
What the finished NCT03420833 record still lists
NCT03420833 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 1 intervention - of which Cardiac resynchronization therapy pacemaker (CRT-P) is the first listed.
NCT03420833 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03420833 about?
NCT03420833 is a clinical study titled "Metabolic Mapping and Cardiac Resynchronization". The purpose of this study is to gather information on the safety and effectiveness of cardiac resynchronization therapy (CRT) in patients who have mild heart failure (HF) and left bundle branch block (LBBB).
What is the current status of trial NCT03420833?
This trial is currently completed. It is a NA study. The enrollment target is 82 participants. The study started on 2018-08-20. Estimated completion is 2023-12-19.
What interventions are being tested in trial NCT03420833?
The interventions under investigation include: Cardiac resynchronization therapy pacemaker (CRT-P) (DEVICE).
Who is sponsoring clinical trial NCT03420833?
This trial is sponsored by Yong-Mei Cha, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03420833's enrollment target sits among peer trials
82 990th of 2000 higher than 1,009 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI